Arama Sonuçları - Can Cai

  • Gösterilen 1 - 5 sonuçlar arası kayıtlar. 5
Sonuçları Daraltın
  1. 1
    SVM-Prot: web-based support vector machine software for functional classification of a protein from its primary sequence

    SVM-Prot: web-based support vector machine software for functional classification of a protein from its primary sequence Yazar: Can Cai

    Baskı/Yayın Bilgisi 2003
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine

    Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine Yazar: Edith A. Perez, Guillermo Lerzo, Xavier Pivot, Eva Thomas, Linda T. Vahdat, Linda D. Bosserman, Patrice Viens, Can Cai, Brian P. Mullaney, Ronald Peck, Gabriel N. Hortobágyi

    Baskı/Yayın Bilgisi 2007
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development

    Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development Yazar: Kunlun He, Xiwen Zhu, Yan Liu, Chunmu Miao, Tao Wang, Peizhi Li, Lei Zhao, Yaxi Chen, Junhua Gong, Can Cai, Jinzheng Li, Shengwei Li, Xiong Z. Ruan, Jianping Gong

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

    Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial Yazar: Robert J. Motzer, Camillo Porta, Nicholas J. Vogelzang, Cora N. Sternberg, Cezary Szczylik, Jakub Żołnierek, Christian Kollmannsberger, Sun Young Rha, Georg A. Bjarnason, Bohuslav Melichar, Ugo De Giorgi, Viktor Grünwald, Ian D. Davis, Jae‐Lyun Lee, Emilio Esteban, Gladys Urbanowitz, Can Cai, Matthew Squires, Mahtab Marker, Michael Shi, Bernard Escudier

    Baskı/Yayın Bilgisi 2014
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  5. 5
    Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial

    Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial Yazar: Hongfei Duan, X. Chen, Z. Li, Yu Pang, Wei Jing, P. Liu, Ting Wu, Can Cai, Jie Shi, Ziwei Qin, H. Yin, Chao Qiu, C. Li, Yuqing Xia, W. Chen, Z. Ye, Z. Li, Guofeng Chen, Shengjun Wang, Ying Liu, Luis Chu, Min Zhu, Tao Xu, Qi Wang, Jie Wang, Yue Du, Jie Wang, Naihui Chu, Steven Jing‐Liang Xu

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: